Stephen Amann, MD
Gastroenterology · Tupelo, MSNPI 1063471761
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 64.6% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $6,559 and has fallen 92.7% since, to $481 in 2025.
Across 297 payments — averaging $42.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$8K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$422
- Takeda Pharmaceuticals U.S.A., Inc.$329
- Gilead$256
- Johnson & Johnson$241
- plus $2K from 24 others
What the payments were for
- Consulting fees$6,12549%
- Travel & lodging$1,61613%
- Food & beverage$4,77938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $8,085 |
| AbbVie | 118 | $1,485 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $329 |
| Gilead | 13 | $256 |
| Johnson & Johnson | 14 | $241 |
| Boston Scientific | 6 | $215 |
| Sanofi | 10 | $209 |
| Bristol Myers Squibb | 9 | $143 |
| Ironwood Pharmaceuticals, Inc | 9 | $124 |
| Ardelyx, Inc. | 5 | $112 |
| Evoke Pharma, Inc. | 2 | $111 |
| Nestle Healthcare Nutrition Inc. | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $96 |
| Pfizer | 5 | $80 |
| QOL Medical, LLC | 4 | $76 |
| Lilly USA, LLC | 3 | $63 |
| Intercept Pharmaceuticals, Inc. | 3 | $53 |
| Merck | 3 | $44 |
| Biocompatibles, Inc. | 2 | $42 |
| Aimmune Therapeutics, Inc. | 3 | $41 |
| Amgen | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Romark Laboratories, LC | 1 | $17 |
| Intra-sana Laboratories | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Enterra Medical, Inc. | 1 | $13 |
| Organon | 1 | $5 |
How this compares
$12,520 in reported general payments places this provider in the 85th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $76,264 |
| CreonLipase/Protease/Amylase | 13 | $63,514 |
| ZenpepLipase/Protease/Amylase | 21 | $54,530 |
| XifaxanRifaximin | 11 | $32,922 |
| LinzessLinaclotide | 55 | $27,511 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 207 | $13,658 |
| MovantikNaloxegol Oxalate | 11 | $4,524 |
| Ursodiol | 46 | $3,582 |
| Mesalamine | 21 | $3,306 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 20 | $3,241 |
| Pantoprazole Sodium | 103 | $2,433 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 16 | $2,283 |
| Famotidine | 265 | $2,195 |
| Budesonide DrBudesonide | 14 | $2,152 |
| CholestyramineCholestyramine (With Sugar) | 24 | $1,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,485 | $91,02568 claims |
| Aimmune Therapeutics, Inc.Zenpep | $41 | $54,53021 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $422 | $35,20527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Tupelo
- John PhillipsTupelo$150K
- Christopher DeckerTupelo$6K
- Wassem JuakiemBiloxi$519K
- Reed HoganFlowood$216K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
- Vonda ReevesFlowood$39K
- Ernest WilliamsOxford$38K
- Reed HoganFlowood$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.